Further analysis of the five tumor types with highest prevalence of KRAS mutations revealed an association in PAAD and READ, whereby KRAS-mutated tumors displayed lower expression of the c-Score versus KRAS wild-type tumors (Fig. 6e; MSI status was controlled using MANTIS for READ (P = 0.016, multivariate linear regression), while PAAD did not include cases with MSI). The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.